Is Bluesky the new Twitter (X) for academic research conversations? Learn how Medical Affairs teams can maximize the opportunity of this new platform.
Pharma launch plans often overlook a critical driver of success: a formal insights strategy.
In what is certainly a new high or a new low for this podcast, we explore how to calculate the “Kardashian Index” of your KOLs and scientific leaders.
Johnson & Johnson’s Medical Affairs team is transforming strategy with data-driven insights, moving beyond traditional approaches to identify key opinion leaders, improve advisory board diversity, and enhance patient journey mapping. With H1’s analytics, they are shifting from quantity to quality in engagements, advancing health equity, and leveraging AI for smarter decision-making.
In this On-Demand webinar, you will focus on key learnings from the pilot and explore expansion in usage of this emerging technology.
The objective of this article is to discuss the paradigm shift in how companies plan for and deliver on the “long tail” of a drug’s impact even after Loss of Exclusivity (LoE) – a process known as lifecycle management (LCM).
In this On-Demand webinar, you will discover how to view a demo on the use of GenAI in data fact validation, learn key lessons in implementing GenAI-based medical and regulatory checks, explore how to address potential gaps and identify opportunities to scale.
This white paper draws on the collective expertise of ten leading professionals in scientific communications and stakeholder engagement, as well as members of the Medical Affairs Professional Society. Their areas of specialization include medical and scientific communications, omnichannel engagement, digital strategy, medical information and field medical operations.
In this webinar, we will share how to realize the potential of insights starts with a focus on strategy
In this webinar we discuss the best practices and hurdles to implement tangible medical affairs impact measurement.